|Bid||163.46 x 800|
|Ask||163.94 x 800|
|Day's Range||162.96 - 164.06|
|52 Week Range||133.65 - 179.92|
|Beta (5Y Monthly)||0.72|
|PE Ratio (TTM)||24.47|
|Earnings Date||Oct. 19, 2021|
|Forward Dividend & Yield||4.24 (2.59%)|
|Ex-Dividend Date||Aug. 23, 2021|
|1y Target Est||188.29|
AstraZeneca (NASDAQ: AZN) awaits U.S. Emergency Use Authorization for its COVID-19 antibody therapy as a prophylaxis. In this Motley Fool Live video recorded on Oct. 13, Motley Fool contributors Keith Speights and Brian Orelli discuss how effective AstraZeneca might be in competing against antibody therapies marketed by COVID-19 antibody therapies already on the market.
In this Motley Fool Live video recorded on Oct. 13, Fool contributors Keith Speights and Brian Orelli discuss two upcoming U.S. Food and Drug Administration (FDA) approval decisions that investors should keep an eye on. Keith Speights: Brian, on another note, the FDA is set to make several important approval decisions in the fourth quarter. Brian Orelli: Biomarin (NASDAQ: BMRN) has one coming up on Nov. 20.
(Bloomberg) -- Johnson & Johnson can’t immediately halt lawsuits claiming the company’s talc baby powder hurt tens of thousands of women, a federal judge ruled.Most Read from BloombergWhy Americans and Britons Are Rushing to Buy Idyllic Homes in ItalyThe Top Money Maker at Deutsche Bank Reaps Billions From SingaporeOne of California’s Wealthiest Counties Could Run Out of Water Next SummerCities' Answer to Sprawl? Go Wild.The Coming Electric Car Disruption That Nobody’s Talking AboutU.S. Bankrupt